Drugs / Ralimetinib
Ralimetinib
also known as
LY2228820 · LSN-2322600 · LSN-2322600 FREE BASE · LY2228820 dimesylate · LY22288220 · Ralimetinib mesilate · RALIMETINIB MESYLATE · ZZ-84
Small molecule targets MAPK14 via inhibition
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02860780 | Aug 2016 → May 2017 | cancer of unknown primary site, colorectal cancer, metastatic malignant neoplasm, non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01393990 | Sep 2008 → Feb 2013 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02364206 | Jun 2015 → Aug 2019 | adult glioblastoma | Centre Jean Perrin | Completed | No outcome recorded |
| Phase 1/2 | NCT01663857 | Jul 2012 → May 2017 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02322853 | Jan 2015 → Apr 2017 | breast cancer | Centre Francois Baclesse | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ralimetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02322853 ↗ |
| Known as | LSN-2322600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364626 ↗ |
| Known as | LSN-2322600 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364626 ↗ |
| Known as | LY2228820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01393990 ↗ |
| Known as | LY2228820 dimesylate | “LY2228820 dimesylate (Ralimetinib) will be administered orally” NCT02322853 ↗ |
| Known as | LY22288220 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364626 ↗ |
| Known as | Ralimetinib mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364626 ↗ |
| Known as | RALIMETINIB MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364626 ↗ |
| Known as | ZZ-84 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364626 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL2364626 ↗1“p38 MAPK Inhibitor” NCT01393990 ↗ |
| Modality | Small molecule | — CHEMBL2364626 ↗ |
| Route | Oral | “Administered orally” NCT01393990 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL2364626 ↗ |